Literature DB >> 21394462

Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease.

Tomoki Aomatsu1, Atsushi Yoden, Kyoichi Matsumoto, Emi Kimura, Keisuke Inoue, Akira Andoh, Hiroshi Tamai.   

Abstract

BACKGROUND: Studies evaluating the correlation between endoscopic disease activity and noninvasive markers are scarce in inflammatory bowel disease (IBD). AIM: The aim of this study is to evaluate the accuracy of the fecal calprotectin (FC) assay as a marker of disease activity of IBD, as determined by an extensive endoscopic scoring system.
METHODS: Thirty-five children and adolescents with IBD [17 with ulcerative colitis (UC) and 18 with Crohn's disease (CD)] and 28 healthy volunteers were enrolled. FC levels were determined by ELISA. The sum of Matts' score for UC and the simple endoscopic score for Crohn's disease (SES-CD) were used. The ileal lesions were evaluated by ultrasonography.
RESULTS: In UC patients, there was a strong correlation between FC levels and the sum of Matts' score (r=0.838, p<0.01). FC levels were significantly elevated in endoscopically active patients (median 1,562.5 μg/g) as compared to patients in endoscopic remission (median 38.9 μg/g) or healthy controls (median 19.9 μg/g). In CD patients, there was a strong correlation between FC levels and the SES-CD score (r=0.760, p<0.01). The FC levels were significantly higher in endoscopically active patients (median 2,037.5 μg/g) than in endoscopically inactive patients (median 172.5 μg/g) or healthy controls (median 19.9 μg/g), respectively. The FC levels of patients with ileal wall thickening (median 2,225.0 μg/g) were significantly higher than healthy controls (median 19.9 μg/g) and patients lacking ileal wall thickening (median 17.5 μg/g), respectively.
CONCLUSIONS: The FC assay is a useful marker for the detection of mucosal inflammation in pediatric IBD patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21394462     DOI: 10.1007/s10620-011-1633-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

Review 1.  Review article: biological activity markers in inflammatory bowel disease.

Authors:  D Desai; W A Faubion; W J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2007-01-08       Impact factor: 8.171

2.  The value of rectal biopsy in the diagnosis of ulcerative colitis.

Authors:  S G MATTS
Journal:  Q J Med       Date:  1961-10

3.  Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.

Authors:  Lamia Kallel; Imen Ayadi; Samira Matri; Monia Fekih; Nadia Ben Mahmoud; Moncef Feki; Sami Karoui; Bechir Zouari; Jalel Boubaker; Naziha Kaabachi; Azza Filali
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-03       Impact factor: 2.566

4.  Indications for investigation of chronic gastrointestinal symptoms.

Authors:  R M Beattie; J A Walker-Smith; S H Murch
Journal:  Arch Dis Child       Date:  1995-10       Impact factor: 3.791

5.  Faecal calprotectin in children with chronic gastrointestinal symptoms.

Authors:  Alan Bremner; Sohere Roked; Rebecca Robinson; Ian Phillips; Mark Beattie
Journal:  Acta Paediatr       Date:  2005-12       Impact factor: 2.299

6.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

7.  Detection of ileocecal Crohn's disease using ultrasound as the primary imaging modality.

Authors:  E J C Sturm; L P J Cobben; M A C Meijssen; S D J van der Werf; J B C M Puylaert
Journal:  Eur Radiol       Date:  2004-02-04       Impact factor: 5.315

8.  Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.

Authors:  G T Ho; H M Lee; G Brydon; T Ting; N Hare; H Drummond; A G Shand; D C Bartolo; R G Wilson; M G Dunlop; I D Arnott; J Satsangi
Journal:  Am J Gastroenterol       Date:  2009-02-17       Impact factor: 10.864

9.  Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease.

Authors:  Sara Ashorn; Teemu Honkanen; Kaija-Leena Kolho; Merja Ashorn; Tuuli Välineva; Bo Wei; Jonathan Braun; Immo Rantala; Tiina Luukkaala; Sari Iltanen
Journal:  Inflamm Bowel Dis       Date:  2009-02       Impact factor: 5.325

Review 10.  What predicts mucosal inflammation in Crohn's disease patients?

Authors:  Itta M Minderhoud; Melvin Samsom; Bas Oldenburg
Journal:  Inflamm Bowel Dis       Date:  2007-12       Impact factor: 5.325

View more
  33 in total

Review 1.  Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice.

Authors:  Britt Christensen; David T Rubin
Journal:  Curr Gastroenterol Rep       Date:  2016-01

2.  Fecal Calprotectin: Diagnostic Accuracy of the Immunochromatographic CalFast Assay in a Pediatric Population.

Authors:  Oriano Radillo; Lorella Pascolo; Stefano Martelossi; Sara Dal Bo; Alessandro Ventura
Journal:  J Clin Lab Anal       Date:  2016-02-15       Impact factor: 2.352

3.  Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease.

Authors:  Akira Andoh; Hiroyuki Kuzuoka; Tomoyuki Tsujikawa; Shiro Nakamura; Fumihito Hirai; Yasuo Suzuki; Toshiyuki Matsui; Yoshihide Fujiyama; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2012-05-11       Impact factor: 7.527

4.  CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis.

Authors:  Maria Lampinen; Amanda Waddell; Richard Ahrens; Marie Carlson; Simon P Hogan
Journal:  J Leukoc Biol       Date:  2013-07-31       Impact factor: 4.962

5.  Altered gut microbiota in Rett syndrome.

Authors:  Francesco Strati; Duccio Cavalieri; Davide Albanese; Claudio De Felice; Claudio Donati; Joussef Hayek; Olivier Jousson; Silvia Leoncini; Massimo Pindo; Daniela Renzi; Lisa Rizzetto; Irene Stefanini; Antonio Calabrò; Carlotta De Filippo
Journal:  Microbiome       Date:  2016-07-30       Impact factor: 14.650

Review 6.  Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review.

Authors:  Ioannis D Kostakis; Kyriaki G Cholidou; Aristeidis G Vaiopoulos; Ioannis S Vlachos; Despina Perrea; George Vaos
Journal:  Dig Dis Sci       Date:  2012-08-17       Impact factor: 3.199

7.  Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease.

Authors:  Raluca Vrabie; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

8.  Geophagy is associated with environmental enteropathy and stunting in children in rural Bangladesh.

Authors:  Christine Marie George; Lauren Oldja; Shwapon Biswas; Jamie Perin; Gwenyth O Lee; Margaret Kosek; R Bradley Sack; Shahnawaz Ahmed; Rashidul Haque; Tahmina Parvin; Ishrat J Azmi; Sazzadul Islam Bhuyian; Kaisar A Talukder; Shahnaij Mohammad; Abu G Faruque
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

9.  Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.

Authors:  Jernej Dolinšek; Petra Rižnik; Larisa Sabath; Dušanka Mičetić-Turk
Journal:  Wien Klin Wochenschr       Date:  2015-12-10       Impact factor: 1.704

10.  Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients.

Authors:  Wei-Chen Lin; Jau-Min Wong; Chien-Chih Tung; Ching-Pin Lin; Jen-Wei Chou; Horng-Yuan Wang; Ming-Jium Shieh; Chin-Hao Chang; Heng-Hsiu Liu; Shu-Chen Wei
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.